Aberrant Promoter Methylation of DLEC1, a Critical 3p22 Tumor Suppressor for Renal Cell Carcinoma, is Associated With More Advanced Tumor Stage

Zhang, Qian; Ying, Jianming; Li, Jisheng; Fan, Yichao; Poon, Fan Fong; Ng, Ka Man; Tao, Qian; Jin, Jie

doi:10.1016/j.juro.2010.03.108

« Previous Next »The Journal of Urology
Volume 184, Issue 2 , Pages 731-737, August 2010

Aberrant Promoter Methylation of DLEC1, a Critical 3p22 Tumor Suppressor for Renal Cell Carcinoma, is Associated With More Advanced Tumor Stage

Qian Zhang
- Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, China
- National Research Center for Genitourinary Oncology, China
- Joint Center for Cancer Epigenetics, China
- Equal study contribution.
Jianming Ying
- National Research Center for Genitourinary Oncology, China
- Joint Center for Cancer Epigenetics, China
- Department of Pathology, Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
- Equal study contribution.
Jisheng Li
- Cancer Epigenetics Laboratory, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China
Yichao Fan
- Cancer Epigenetics Laboratory, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China
Fan Fong Poon
- Cancer Epigenetics Laboratory, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China
Ka Man Ng
- Cancer Epigenetics Laboratory, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China
Qian Tao
- National Research Center for Genitourinary Oncology, China
- Joint Center for Cancer Epigenetics, China
- Cancer Epigenetics Laboratory, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China
- Correspondence: Room 315, Cancer Center, PWH, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong, China (telephone: 852-2632-1340; FAX: 852-2648-8842)
Jie Jin
- Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, China
- National Research Center for Genitourinary Oncology, China
- Joint Center for Cancer Epigenetics, China
- Correspondence: Department of Urology, Peking University First Hospital, Beijing, China (telephone: (86) 10-66551122-2627; FAX: (86) 10-66175710)